Transoral Robotic Surgery in the Nordic Countries : Current Status and Perspectives by Mäkitie, Antti A. et al.
PERSPECTIVE
published: 27 July 2018
doi: 10.3389/fonc.2018.00289






Department of Otolaryngology Head









This article was submitted to
Head and Neck Cancer,
a section of the journal
Frontiers in Oncology
Received: 01 March 2018
Accepted: 09 July 2018
Published: 27 July 2018
Citation:
Mäkitie AA, Keski-Säntti H,
Markkanen-Leppänen M, Bäck L,
Koivunen P, Ekberg T, Sandström K,
Laurell G, von Beckerath M, Nilsson
JS, Wahlberg P, Greiff L, Norberg
Spaak L, Kjærgaard T, Godballe C,
Rikardsen O, Channir HI, Rubek N and
von Buchwald C (2018) Transoral
Robotic Surgery in the Nordic
Countries: Current Status and
Perspectives. Front. Oncol. 8:289.
doi: 10.3389/fonc.2018.00289
Transoral Robotic Surgery in the
Nordic Countries: Current Status and
Perspectives
Antti A. Mäkitie 1,2*, Harri Keski-Säntti 1, Mari Markkanen-Leppänen 1, Leif Bäck 1,
Petri Koivunen 3, Tomas Ekberg 4, Karl Sandström 4, Göran Laurell 4,
Mathias von Beckerath 5, Johan S. Nilsson 6, Peter Wahlberg 6, Lennart Greiff 6,
Lena Norberg Spaak 7, Thomas Kjærgaard 8, Christian Godballe 9, Oddveig Rikardsen 10,
Hani Ibrahim Channir 11, Niclas Rubek 11 and Christian von Buchwald 11
1Department of Otorhinolaryngology – Head and Neck Surgery, University of Helsinki and Helsinki University Hospital,
Helsinki, Finland, 2Division of Ear, Nose and Throat Diseases, Department of Clinical Sciences, Intervention and Technology,
Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, 3Department of Otorhinolaryngology – Head
and Neck Surgery, Oulu University Hospital, Oulu, Finland, 4Department of Surgical Sciences, Uppsala University, Uppsala,
Sweden, 5Department of Otorhinolaryngology – Head and Neck Surgery, Örebro University Hospital, Örebro, Sweden,
6Department of Otorhinolaryngology – Head and Neck Surgery, Skåne University Hospital, Lund, Sweden, 7Department of
Otorhinolaryngology – Head and Neck Surgery, Umeå University Hospital, Umeå, Sweden, 8Department of
Otorhinolaryngology – Head and Neck Surgery, Aarhus University Hospital, Aarhus, Denmark, 9Department of
Otorhinolaryngology – Head and Neck Surgery, Odense University Hospital, Odense, Denmark, 10Department of
Otorhinolaryngology – Head and Neck Surgery, University Hospital North Norway, Tromsoe, Norway, 11Department of
Otorhinolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet, University of Copenhagen, Copenhagen,
Denmark
Background: The five Nordic countries with a population of 27M people form a rather
homogenous region in terms of health care. The management of head and neck cancer
is centralized to the 21 university hospitals in these countries. Our aim was to gain an
overview of the volume and role of transoral robotic surgery (TORS) and to evaluate the
need to centralize it in this area as the field is rapidly developing.
Materials and Methods: A structured questionnaire was sent to all 10 Departments of
Otorhinolaryngology—Head and Neck Surgery in the Nordic countries having an active
programme for TORS in December 2017.
Results: The total cumulative number of performed robotic surgeries at these 10 Nordic
centers was 528 and varied between 5 and 240 per center. The median annual number
of robotic surgeries was 38 (range, 5–60). The observed number of annually operated
cases remained fairly low (<25) at most of the centers.
Conclusions: The present results showing a limited volume of performed surgeries call
for considerations to further centralize TORS in the Nordic countries.
Keywords: head and neck, surgery, management, centralization, cancer
INTRODUCTION
The five Nordic countries (Denmark, Finland, Iceland, Norway, and Sweden) with a population
of 27M people form a rather homogenous region in terms of health care. The planning and the
treatment for head and neck cancer (HNC) for all patients is centralized to the 21 university
hospitals only (1). It is regulated by governmental authorities and organized by the public health
care system in a fairly unified manner in all of the countries.
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Robotic surgery forms an interesting approach in HNC
management, but the technical setting has so far warranted a
remarkable financial investment, which has obviously resulted in
a limited popularity and shared use of existing robots between
several surgical specialties at each institution. Since its first
use in transoral surgery in 2005 only a limited number of
HNC centers worldwide have so far adopted this treatment
modality (2, 3). However, along with the increasing incidence
of HPV-related oropharyngeal squamous cell cancer (OPSCC)
in the Western world the robotic technology continues to
develop, and its indications seem to expand to new areas
in the management head and neck tumors. Therefore, many
Departments of Otorhinolaryngology—Head and Neck Surgery
(ORL - HNS) consider including TORS as an option in their
surgical armamentarium.
We performed a survey in the Nordic countries aiming to
evaluate the current use of transoral robotic surgery (TORS) at
the Departments of ORL - HNS. The results of the study might
offer tools for initiatives to centralize this treatment modality
or to even consider prospective multicenter studies in order to
implement evidence-based TORS.
MATERIALS AND METHODS
TORS is performed at three (Copenhagen, Århus, Odense) out of
the four university hospitals, which manage the HNC treatment
in Denmark (5.7M), at two (Helsinki and Oulu) out of the five
in Finland (5.5M), at one (Tromsoe) out of the four in Norway
(5.2M), and at four (Lund, Örebro, Umeå, Uppsala) out of the
seven in Sweden (10M). Iceland has not yet initiated a TORS
programme. The number of inhabitants in these referral areas
varies from 0.5 to 2.1M (total population 27M).
A structured questionnaire was sent in December 2017 to
all 10 Nordic Departments ORL – HNS performing TORS. The
following data were recorded: the number of inhabitants in
the referral area as well as patients referred for TORS from
abroad, date of the start of robotic surgery, number of robots
and their model, number of surgeons performing TORS, other
specialties using the same robot, availability of the robot, surgical
indications, and number of performed surgeries specified for
each anatomical subsite.
RESULTS
The Department of ORL-HNS at the Lund University Hospital
has used robotic surgery since 2008. The hospital currently has
four robots available, whereas all the other centers have started
TORS after 2013 and have only one robot dedicated for their
use. Solely the Department of ORL-HNS in Copenhagen has
their own robot in contrast to all the other centers, which share
operative time slots with one to seven other surgical specialties.
Half of the reported centers reported insufficient time slots to
utilize the robot. All centers currently use the Da Vinci Si model
except Aarhus and Odense University Hospitals, which are using
the Xi model. The number of trained robotic surgeons for TORS
varies from one to three at each Head and Neck center.
The total cumulative number of performed robotic surgeries
by the end of 2017 at the 10 centers was 528 and varied
between 5 and 240 per center. The median annual number of
robotic surgeries was 38 (range, 5–60). The main indication
for TORS was the treatment of various neoplasms (N = 423).
The remaining indications consisted of diagnostic lingual
tonsil resections in cases with head and neck carcinoma with
unknown primary (HN-CUP), various benign lesions, and of
tonsillectomies for training purposes in the initial learning phase
of TORS. One center in Sweden and one in Denmark reported
having operated on TORS patients also from abroad.
Table 1 shows the distribution of anatomical subsites for
tumor resections in this series. The most frequent resection site
was base of the tongue (53%). There were no reported TORS
operations performed for laryngeal glottic tumors.
DISCUSSION
In this study we performed a survey on the performance of
robotic head and neck surgery at the Departments of ORL-
HNS in the five Nordic countries to be able to consider the
need and possibilities to centralize this treatment modality in
this area with a total of 27M people. Therefore, it remains
obvious that although the technology has been available for more
than 10 years, there are currently only 10 centers out of the 21
Departments of ORL-HNS in the Nordic countries that utilize
TORS. Furthermore, it is noteworthy, that in the Baltic countries
(Estonia, Latvia, Lithuania; total 6M people) there are currently
no surgical robots available. The present study thus covers the
whole Northern Europe. However, along with the increasing
numbers of OPSCC in the Western world and the improved
technical solutions and new surgical indications, robotic surgery
may be popularized even more among the institutions managing
HNC.
Chen et al. concluded from their National Cancer Database
data (n = 877) for adults with OPSCC who had undergone
TORS, that high-volume centers have the lowest rates of positive
margins and unplanned readmissions (4). Similar results were
reported by Cracchiolo et al. (5) in a series of 846 OPSCC
cases undergoing TORS: positive margin rates were lower
when TORS was performed at a high volume vs. low volume
hospital (8.2 vs. 16.7% respectively, p = 0.001) (5). It has been
TABLE 1 | Distribution of the anatomical subsites for tumor resections in the
series of 484 TORS cases in the Nordic countries during the 10-year period
between 2008 and 2017.
Subsite Number (%) of surgeries
Base of tongue* 255 (53)






*The number of base of tongue resections includes the lingual tonsil resections performed
as part of the HN-CUP diagnostic work up.
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suggested that consolidating TORS procedures of early stage
OPSCC to create high-volume centers of excellence might be
a potential strategy to increase incremental effectiveness and
reduce incremental costs (6). For other surgical fields there
are reports advocating for the centralization of robotic surgery
in order to establish high-volume centers with better training
possibilities and consequently more efficient use of operating
time and thus reduced costs (7–10). The results of the present
survey call for considerations to centralize TORS in the Nordic
countries. The observed number of annually operated cases
(median 38) was fairly low (<25) at most of the centers i.e., at
nine out of the ten university hospitals. This result is obviously
slightly biased since two of the ten centers had started their TORS
activities shortly before the survey and could thus not report their
annual number of operated cases. Both of these centers (Odense
and Umeå) have now operated 2–4 patients per month during
the past weeks, which will eventually affect the median number
of annually operated TORS cases in these areas. At the time of
the survey in December 2017 only the Copenhagen University
Hospital reported one TORS case performed on average each
week (total number of 240 cases since 2013) (11). Furthermore,
in Iceland, the Department of ORL-HNS does not utilize a robot
and in Norway, only one center (Tromsoe) has adopted this
technology in 2016 and has now the experience of 37 surgeries.
Since the introduction of TORS more than a decade ago, the
indications for robotic surgery in the head and neck area have
expanded from including oropharyngeal tumors to neoplasms
of the nasopharynx, hypopharynx, larynx and thyroid, and
most recently also skull base and neck dissection. The typical
anatomical subsite for the primary tumor in the present series
was either in the palatine or lingual tonsils, which are easily
accessible with TORS. Half of the TORS procedures involved the
base of the tongue, which has been shown also by others (11).
This is the result of the increasing number of HNC cases with
HPV-related HN-CUP and the paradigm of using robotic surgery
in the clinical work up of these cases (12, 13).
Successful TORS for laryngeal neoplasms has been mainly
restricted to involve supraglottic lesions, which was also observed
in the present series. Supraglottic laryngectomy has become
one of the standard TORS approaches and several reports
have suggested expanding the use of robotic surgery in the
management of laryngeal cancer (14). In comparison with
the conventional transoral laser surgery, most TORS surgeons
use monopolar diathermy although robotic laser instruments
are available. Additionally, the access to larynx has been
limited by technical factors (mouth retractors, collision of
instruments in narrow spaces). The context of applying TORS
for laryngeal surgery is now facing a new era with the first
reported experiences of a novel semi-rigid operator-controlled
robotic system (Medrobotics Flex system) (15). Furthermore,
a recent safety and feasibility trial of the da Vinci Single Port
(Intuitive Surgical Inc., Sunnyvale, CA, USA) demonstrates
that this flexible single-arm device is safe and feasible in
performing TORS to access nasopharynx, oropharynx, larynx,
and hypopharyngeal areas (16). The development of these
new technologies emphasizes the need to consider centralized
management of TORS in the Nordic countries.
The current setting for TORS in general clearly involves
certain limitations, some of which are related to the da Vinci
Surgical System i.e., instrumental and annual service costs.
Nevertheless, the costs may be reduced by sharing the robotic
instrument in between specialties. In high-volume centers, the
set-up (docking) of robot and placement of the mouth retractor
have improved quickly over time. Absence of tactile feedback
and limited exposure for certain areas of the upper aerodigestive
tract still call for further improvement (17). However, the
increasing incidence of HPV-related oropharyngeal cancers and
the observed improved outcome after surgical treatment in
selected cases form a platform for further development of TORS
(18). These factors warrant continuous actions in terms of system
development and will obviously change the scene for TORS in the
future.
We conclude, that a high volume of surgeries at each
TORS center in the Nordic countries is needed to maintain
a sufficient level of expertise and quality assurance. We also
want to emphasize the potential life-threatening complications
that are related to TORS and need to be considered in the
learning curve phase at each center. Five out of the ten
centers in the present survey reported having experienced major
postoperative bleeding episodes (data not shown). Therefore, this
study has value in describing the current status with TORS in
the Nordic countries. Importantly, it also forms the initial steps
in creating a forum between TORS surgeons at the respective
centers, which is needed to design multicentre studies. Finally,
it emphasizes the need for future reflections on where we
are headed in terms of TORS in the field of head and neck
surgery.
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